{"_id":"zfClK1A6ztV7FpqzcITPezevIDRIpdoNeOQXsVCu1gcRthvZyo6haf","founded_year":1979,"lastupdate":"2024-10-21T00:00:00.000Z","update_date":"2024-10-21T00:00:00.000Z","lastModified":"Apr 22, 2026","confidence_score":59,"active":1,"confidence_score_reason":"product stage, sector, tags, business model, video or image, funding rounds, markets, not claimed","urlname":"boston-scientific","minimal_profile":null,"status":"Public","fullstatus":"Public on NYSE on May, 1992;","acquired":0,"description_edited":null,"tag_line_edited":null,"phone":null,"registrar":null,"biverification":"Maor Perlov","recentupdates":[{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-02 06:03:13.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-02 06:03:13.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-02 06:01:43.000000","last_name":"Perlov","first_name":"Maor"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-12-22 06:38:48.000000","last_name":"Levin","first_name":"Eran"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-02 05:56:19.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-07-31 12:00:48.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-02 05:54:38.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2024-10-21 11:22:31.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-02 05:53:55.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-02 05:53:47.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-02 05:57:12.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-02 05:53:47.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Automatic","datetime":"2023-08-02 05:58:47.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-02 06:01:43.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-07-31 12:00:33.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Automatic","datetime":"2023-07-31 12:00:39.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2024-10-21 11:22:30.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-02 05:55:44.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-02 06:00:50.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-07-31 12:00:33.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-02 05:53:55.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-02 05:56:22.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-02 06:02:48.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Automatic","datetime":"2023-08-02 05:58:53.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-07-31 12:00:48.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-02 06:03:13.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-02 05:58:47.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-02 05:56:19.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Automatic","datetime":"2023-08-02 05:58:47.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-02 06:03:59.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-02 06:01:43.000000","last_name":"Perlov","first_name":"Maor"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-12-05 14:36:46.000000","last_name":"Levin","first_name":"Eran"},{"email":"maor.perlov@sncentral.org","source":"Automatic","datetime":"2024-10-21 10:56:02.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2024-10-21 11:19:13.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2024-10-21 11:19:09.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-02 05:57:06.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Automatic","datetime":"2024-10-21 10:56:02.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2024-10-21 11:18:18.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2024-10-21 11:18:18.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-02 05:55:45.000000","last_name":"Perlov","first_name":"Maor"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-12-05 15:00:00.000000","last_name":"Levin","first_name":"Eran"},{"email":"matane@sncentral.org","source":"Automatic","datetime":"2025-03-09 13:06:02.000000","last_name":"Eblagon","first_name":"Matan"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2024-10-21 11:08:50.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-02 06:03:13.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-02 05:57:12.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-02 05:57:06.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-02 05:55:44.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-02 05:54:38.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2024-10-21 11:16:15.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-02 05:54:38.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-02 05:57:11.000000","last_name":"Perlov","first_name":"Maor"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-08-07 05:07:35.000000","last_name":"Levin","first_name":"Eran"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-02 05:53:47.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-02 05:55:04.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-02 05:55:45.000000","last_name":"Perlov","first_name":"Maor"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2025-02-06 12:37:46.000000","last_name":"Levin","first_name":"Eran"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-07-31 12:00:48.000000","last_name":"Perlov","first_name":"Maor"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-08-07 05:07:35.000000","last_name":"Levin","first_name":"Eran"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-02 05:53:55.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Automatic","datetime":"2023-08-02 05:58:47.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-02 05:54:34.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2024-10-21 11:12:14.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-02 05:59:17.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-02 05:54:38.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Automatic","datetime":"2023-07-31 12:00:39.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-07-31 12:00:48.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-07-31 12:01:11.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2024-10-21 11:19:13.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-07-31 12:00:48.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-02 06:00:15.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-02 05:53:55.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-02 06:01:43.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-02 05:55:39.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-02 05:59:17.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-02 05:53:47.000000","last_name":"Perlov","first_name":"Maor"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-08-07 05:48:02.000000","last_name":"Levin","first_name":"Eran"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-02 06:03:59.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-02 05:54:34.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-02 05:55:39.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-02 06:03:59.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-02 06:05:59.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-02 05:55:39.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-02 05:55:04.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-02 05:57:11.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-02 05:59:17.000000","last_name":"Perlov","first_name":"Maor"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-12-05 14:18:09.000000","last_name":"Levin","first_name":"Eran"},{"email":"maor.perlov@sncentral.org","source":"Automatic","datetime":"2023-08-02 05:58:47.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-07-31 12:00:33.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Automatic","datetime":"2024-10-21 11:21:40.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-02 05:59:17.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-07-31 12:00:48.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-02 05:56:22.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Automatic","datetime":"2023-08-02 05:58:47.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-02 05:55:39.000000","last_name":"Perlov","first_name":"Maor"}],"sectorverify":null,"biverify":{"id":"7JMVZ1cDkplo2zZFEs4WRWhuj0xt9r8fRw5ZIjvtKeO50MH4vxhFbX","fullname":"Maor Perlov"},"biverifydate":"2024-10-21T00:00:00.000Z","crunchbaseid":"boston-scientific","lastupdator":"Maor Perlov","lastupdator_email":"maor.perlov@sncentral.org","creator":"Maor Perlov","creator_email":"maor.perlov@sncentral.org","createdate":"2023-07-31T00:00:00.000Z","lastupdatedate":"2024-10-21","hide_reason":null,"hide_reason_data":null,"logokey":"$RH4cKLPIzbWARH9LQZDsvuKZetnjFnXpTSc06OqvMLyLx28ZDnpzFt.jpg","name":"Boston Scientific","israeliacquisitions":1,"forbesranking":458,"investmentarm":null,"investmentarmname":null,"hubname":null,"acquired_amount":null,"acquired_by":null,"acquired_country":null,"acquired_month":null,"acquired_year":null,"type":"Multinational","formernames":[],"alternativenames":null,"country":"United States","inisraelsince":"4/2000","inisraelsincemonth":"4","isisraeli":0,"marketcapital":141350848419,"marketcapitaldate":"2026-01-01T14:08:33.000Z","oneliner":"Medical Devices and Equipment and Supplies","website":"https://www.bostonscientific.com/","employees":"201-500","employees_exact":351,"employees_overall":"50,000+","employees_overall_exact":51282,"sociallinks":{"twitter":"","youtube":"","facebook":"","linkedin":"https://www.linkedin.com/company/1637","instagram":""},"social":["https://www.linkedin.com/company/1637"],"flattenedsociallinks":"https://www.linkedin.com/company/1637","apps":{"appstore":"","googleplay":""},"investmentstage":[],"about":"Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. It operates through the following segments: Rhythm and Neuro, Cardiovascular and MedSurg. The Rhythm and Neuro segment develops implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. The Cardiovascular segment comprises of technologies or diagnosing and treating coronary artery disease and other cardiovascular disorders including structural heart conditions. The MedSurg segment focuses on Endoscopy, which provides devices to diagnose and treat a broad range of gastrointestinal and pulmonary conditions with innovative and invasive technologies.","founded":"6/1979","team":[{"name":"Dudi Reznick","email":"Dudi.Reznick@bsci.com","phone":"","gender":"Male","userid":"EejcS1CoJHySCH3pJsoCqKGazdPygjScyECfttxiovlgX4tJ6gVaJQ","bounced":false,"claimed":null,"founder":0,"urlname":"dudi-reznick","visible":1,"memberid":"mTsnLRxkFVAkL6RsYmaifQRNe0tC1iJIQ2d9TIwq4hB26niez39rpt","position":"Director, Head of Urology R&D","last_name":"Reznick","claimtoken":null,"first_name":"Dudi","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/dudi-reznick-21054511/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":null,"initials":"DR","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Carmit Yaron-Lehmann ","email":"","phone":"","gender":"Female","userid":"ca1tkeHSx5uNZEOUFOWstgixv8RhilKJaIupZxiROO2KZpTji2yveM","bounced":false,"claimed":null,"founder":0,"urlname":"carmit-yaron-lehmann-1","visible":1,"memberid":"xcCSokOPcuz0ocdBuK6AxP37vf2vsUYXOdFIB2OANcP0lyCMcXNz8E","position":"Head of HR Boston Scientific Israel","last_name":"Yaron-Lehmann ","claimtoken":null,"first_name":"Carmit","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/carmityaronlehmann/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":null,"initials":"CY","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Jonathan  Goldstein","email":"Jonathan.Goldstein@bsci.com","phone":"052-844-5000","gender":"Male","userid":"3BmbCrMmKDCBGf5oJOrcj0NdVyg0N9IScl5e9wuCexXHLduKrDK5mw","bounced":false,"claimed":null,"founder":0,"urlname":"jonathan-goldstein","visible":1,"memberid":"WeGfKmcr4IlfKH4lhxKDEhFmveA8HCjmw889l6KNH0QBBjLnPAsoNk","position":"Director, Innovation Strategy and Venture","last_name":" Goldstein","claimtoken":null,"first_name":"Jonathan","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/jgoldstein001/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":null,"initials":"J ","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"portfolio":[{"name":"Rythmia","hidden":false,"raised":"Undisclosed","founded":"2004","fullurl":"/company_page/rythmia","logokey":null,"urlname":"rythmia","employees":"0","company_id":"SNDRZUFazue8Wgr44mHFEZm2LG3cnJUVa7LadEBf5fBoOde1Gg6iwq","description":"Cardiac arrhythmia treatment solutions","fundingstage":"Acquired","businessmodel":"B2B","raisedNumber":0,"logourl":"/assets/empty-state.svg","style":"","hiddenCompanyTooltip":""},{"name":"SoniVie","hidden":false,"raised":"$73.26M","founded":"2014","fullurl":"/company_page/sonivie","logokey":"$fK62VEs0jkCqdIZB4oUcGVya8Ujylw5o4kb1qUlsXs5tJC2OMO9Fro","urlname":"sonivie","employees":"1-10","company_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgKWBqtUJDA","description":"Pulmonary Hypertension Denervation Treatment","fundingstage":"Acquired","businessmodel":"B2B","raisedNumber":73260000,"logourl":"https://storage.googleapis.com/clean-finder-353810/$fK62VEs0jkCqdIZB4oUcGVya8Ujylw5o4kb1qUlsXs5tJC2OMO9Fro","style":"","hiddenCompanyTooltip":""},{"name":"VeinWay","hidden":false,"raised":"$7.43M","founded":"2020","fullurl":"/company_page/veinway","logokey":"$fVXPfVSL2QuaFxsN0ambCQdzMuQpGnr6qxqbfW50sPIiTudQFrvVQB","urlname":"veinway","employees":"1-10","company_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4Kv02KwKDA","description":"Advanced Vein Blockage Crossing Tools","fundingstage":"A","businessmodel":"B2B","raisedNumber":7435000,"logourl":"https://storage.googleapis.com/clean-finder-353810/$fVXPfVSL2QuaFxsN0ambCQdzMuQpGnr6qxqbfW50sPIiTudQFrvVQB","style":"","hiddenCompanyTooltip":""}],"exits":[],"mediagallery":[],"affiliatedOrganizations":null,"address":{"israeli":[{"id":"ewboL5l3q0UV2WRBDqErcv1j7mjpO0VH3arwNmsQdVlqDG5YrfGYqt","city":"Yokne'am Illit","type":["R&D"],"address":"HaKidma St 6, Yokne'am Illit, Israel","placeid":"ChIJc6HDbJOuHRURhAXXMTOdzPQ","notactive":0,"openeddate":"2000-02-21","registrarid":"512944281","firstrdcenter":0,"registrarname":null}],"officesabroad":[{"id":"Sb4ephlqrQR0xie7diTC8lyk7skTzESrLws6DqM0WpUJwT9cn7v9rT","city":"Marlborough","address":"Marlborough, MA, USA","country":"United States","placeid":"ChIJbe5haA6L44kRxK_1VUuq6cc"}]},"headquarter_address":"Marlborough, MA, USA","news":[{"id":"CN7SLXzM0caBoC8nGg0c0rQ89XqJro2OVTARomgPXROteAkgF2hYKP","date":"Apr 22, 2026","link":"https://finance.yahoo.com/markets/world-indices/articles/asian-benchmarks-mixed-cautious-trading-053634167.html","source":"finance.yahoo.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"CjZVMgsx96FkLYNE6ilEB3oBZ7c6IWsSuiAkwPGR2NBPEWUMJPuiWB","news_summary":"US stocks rally toward a record while Brent oil tops $100 on uncertainty about the Iran war","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"3ENzJ6s7Ik0Reh1m84E1ZQR05KGMJ0E13I0YaEqTu4jcAJk2LaY5cT","date":"Dec 23, 2025","link":"https://finance.yahoo.com/news/bway-shares-gain-optum-expanding-170700463.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"insurance coverage","round":null,"company":"BrainsWay Ltd.","layoffs":null,"summary":"BrainsWay Ltd. has announced an expansion of insurance coverage for its Deep TMS therapy for adolescent depression, following Optum Behavioral Healths decision to include eligible adolescents in its medical policy. This expansion is expected to enhance reimbursement visibility and support BrainsWays commercial opportunities by increasing the number of covered lives. The announcement led to a 10.1% increase in BWAY shares, reflecting growing clinical acceptance of Deep TMS. The coverage expansion is anticipated to strengthen BrainsWays position in the market by widening its reimbursable patient base, improving utilization, and encouraging clinics to invest in Deep TMS capacity. The company, with a market capitalization of $334.8 million, projects an earnings growth of 100% for the current year.","partners":null,"customers":"Optum Behavioral Health","eventType":null,"investors":null,"confidence":10,"key_topics":["insurance","expansion","depression","therapy","adolescents"],"date_of_event":null,"product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":"$334.8 million","impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"FDA approved/pending approval":"FDA-cleared","AI technology developing/using":"using","structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Dx2Ftk0ADV8VxGTQOYOJkuIaBo3ZbCZ3dnxcQWoehYSq2rDl7a8CxN","news_summary":"BWAY Shares Gain on Optum Expanding Deep TMS Coverage for Teens","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"e0hBqH7ETgkAyrneUl9XiBL2qhp9d62ZPeD8qMgEBB2cEAgtT0B6Ug","date":"Dec 11, 2025","link":"https://en.globes.co.il/en/article-boston-scientific-transferring-galil-medical-activity-to-ireland-1001529065","source":"en.globes.co.il","visible":1,"analysis":{"tags":"restructuring","round":null,"company":"Boston Scientific","layoffs":100,"summary":"Boston Scientific is closing its Galil Medical subsidiary in Yokne’am, Israel, and transferring its operations to Galway, Ireland, by 2028. This move will affect approximately 100 employees, who have been notified and will have opportunities to apply for other positions within the company. Despite this closure, Boston Scientific continues to invest in Israel, having acquired the laser development and production center from Lumenis in 2021 for $1.1 billion and SoniVie for $360 million earlier this year. Galil Medical, known for its devices that freeze cancerous growths, was acquired by Boston Scientific in 2019 through its purchase of BTG.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["transfer","production","acquisition","employees","oncology"],"date_of_event":"December 11, 2025","product_stage":"released","investment_date":null,"acquired_company":"SoniVie","valuation_amount":null,"impact_on_company":"growth-negative","investment_amount":null,"structured_issues":["Layoffs","Acquisition"],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"structuredIssuesShow":"#Layoffs  #Acquisition","entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"cIjMajlbKKUxGpZsv15u5yTUQf0pQjyCEkHgfof1NSCQCBNVTsk6La","news_summary":"The transfer from Yokne'am to Galway will be completed by 2028. Galil Medical employs about 100 people.","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"Uci5E6qmtP4FxUbshKEnGzHThaLJ4jevowCIOPASWggyGV1FAfw4HK","date":"Dec 1, 2025","link":"https://finance.yahoo.com/news/nyxoah-gains-favorable-cms-reimbursement-141400129.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"reimbursement rates","round":null,"company":"Nyxoah","layoffs":null,"summary":"Nyxoah announced that the U.S. Centers for Medicare & Medicaid Services has finalized the CY2026 Hospital Outpatient Prospective Payment System and Ambulatory Surgery Center Rule, significantly increasing reimbursement rates for Genio hypoglossal nerve stimulation implants. The new rates, effective in 2026, are expected to boost the adoption of Genio implants in the U.S. market. Despite a 40% drop in Nyxoahs shares this year, the increased reimbursement rates could enhance the companys prospects by driving broader adoption and expansion across Medicare-heavy institutions. The Genio implant, which treats obstructive sleep apnea, received FDA approval in August 2023 for a subset of adult patients.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["reimbursement","FDA approval","Genio implant","OSA treatment","ASC rates"],"date_of_event":"2026","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":"approved","AI technology developing/using":"using","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"4jXp91FdI6HUdJM2oswW3KysY1CBZAVNbwxy0nLpNAyuhenh0efXxm","news_summary":"Nyxoah Gains Favorable CMS Reimbursement Ruling for Genio System","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"uJkADHw9iSXVEVhU5ElHqd87gPbuO1KTJfzdvfa7BUYenRYoQIgsSB","date":"Sep 18, 2025","link":"https://finance.yahoo.com/news/entera-bio-unveils-promising-pk-124100416.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"pharmacokinetic data","round":null,"company":"Entera Bio Ltd.","layoffs":null,"summary":"Entera Bio Ltd. recently presented promising pharmacokinetic data for its oral GLP-2 analog therapy for short bowel syndrome (SBS) at the ESPEN Congress. The therapy, developed in collaboration with OPKO Health, aims to offer a more convenient alternative to existing treatments like Gattex, which require daily injections. The data demonstrated significant pharmacological advantages, including a longer plasma half-life and higher peak plasma concentrations compared to current therapies. While still in preclinical development, the therapys potential to address a market worth nearly $800 million annually could drive positive investor sentiment. The collaboration with OPKO Health is crucial for advancing this innovative treatment.","partners":"OPKO Health","customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["pharmacokinetics","oral therapy","SBS market","preclinical data","partnership"],"date_of_event":"September 2023","product_stage":"preclinical","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","Partners"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"BAm4OkNStzYs8n7FuqqZy7qEuLOmY8RWTrrPmSXXqOr1PfvEOla1FY","news_summary":"Entera Bio Unveils Promising PK Data for First Oral GLP-2 Therapy","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"wnFbFA0qPYyPA5IvEF2okVgRO9PEjLqj9PCXFhSxWWq7k53WQhaA0J","date":"Sep 9, 2025","link":"https://finance.yahoo.com/news/microbot-shares-rise-fda-clearance-172500511.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"FDA clearance","round":null,"company":"Microbot Medical Inc.","layoffs":null,"summary":"Microbot Medical Inc. has received FDA 510(k) clearance for its LIBERTY Endovascular Robotic System, marking a significant regulatory milestone. This clearance allows the company to commercialize the LIBERTY system in the U.S. market, aiming to expand its presence in the robotic surgery field. The LIBERTY system is designed to enhance precision and safety in endovascular procedures while minimizing radiation exposure. Following the announcement, Microbots shares surged, reflecting investor confidence in the companys growth prospects. The systems unique design is expected to drive faster adoption, offering a competitive advantage over traditional robotic platforms. Microbot plans to continue gathering clinical data as part of its commercial launch strategy.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["FDA clearance","robotic surgery","market entry","radiation reduction","commercialization"],"date_of_event":null,"product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":"$166.7 million","impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","FDA approved/pending approval"],"acquisition_amount":null,"FDA approved/pending approval":"approved","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage  #FDA approved/pending approval","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"oV28szn8Cjh8FDCEyz7UG6YtnZo0zyciQkGwffdy8g8JUFE2Ksmuut","news_summary":"Microbot Shares Rise on FDA Clearance for LIBERTY Robotic System","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"nGzgy2IkrX4ChKEJzBQECHTdx9tPxDViVZud66ilJR0CVBgjqBlpsE","date":"Aug 22, 2025","link":"https://finance.yahoo.com/news/bway-shares-rise-strategic-investment-173000484.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"investment","round":null,"company":"BrainsWay Ltd.","layoffs":null,"summary":"BrainsWay Ltd. has made a strategic $5 million investment in Neurolief Ltd., a company developing wearable neuromodulation devices for mental health treatment. This investment allows BrainsWay to expand into the at-home treatment market, complementing its existing Deep TMS platform. Neuroliefs Proliv Rx, designed for Major Depressive Disorder, is pending FDA approval. The investment includes a convertible loan with additional funding contingent on FDA approval and revenue milestones. BrainsWays shares have increased following the announcement, reflecting positive market reception. The collaboration aims to diversify revenue streams and strengthen BrainsWays position in the mental health treatment market.","partners":"Neurolief Ltd.","customers":null,"eventType":null,"investors":"BrainsWay Ltd.","confidence":9,"key_topics":["Investment","Mental Health","Neuromodulation","FDA Approval","Growth"],"date_of_event":null,"product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":"$279.2 million","impact_on_company":"growth-positive","investment_amount":"$5 million","structured_issues":["Investment","Partners","Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":null,"structuredIssuesShow":"#Investment  #Partners  #Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"YNjOSubfBxbqpaR3wh2v9DG7Kb4VoVydaU3Jdm9ZUwTycXtXJ0Mjbl","news_summary":"BWAY Shares Rise on Strategic Investment in Neurolief's At-Home Care","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"fMLegNFto06nRYFEVP3mFGqE8DoQUs62QzIOzGJvNqMfNRMQLeJul2","date":"Aug 21, 2025","link":"https://finance.yahoo.com/news/microbot-shares-rise-u-patent-173300489.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"patent, expansion","round":null,"company":"Microbot Medical Inc.","layoffs":null,"summary":"Microbot Medical Inc. has been granted a new U.S. patent for its LIBERTY Endovascular Robotic System, which enhances its flexibility and broadens its potential applications. This patent expands the companys addressable market from 2.5 million to over six million annual procedures in the U.S., significantly increasing its revenue potential. The patent strengthens Microbots intellectual property portfolio, positioning it for future growth and potential strategic partnerships. While the LIBERTY system is still under FDA review for 510(k) clearance, the patent provides a strategic advantage as the company prepares for commercialization. Following the announcement, Microbots shares rose by 7.1%, and the companys market capitalization is currently $140.7 million.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["patent","LIBERTY","endovascular","market","growth"],"date_of_event":"2023","product_stage":"FDA review","investment_date":null,"acquired_company":null,"valuation_amount":"$140.7 million","impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","FDA approved/pending approval"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage  #FDA approved/pending approval","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"BJtrq5rcqHkwSexfx8WoC9Ce1TO2K9hdysLZKKc9MAffslhqtzdnBs","news_summary":"Microbot Shares Rise as New U.S. Patent Expands LIBERTY System Market","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"J4dJD1pprvGbNl1ZEULgWRWPcYzO869Kzj4pmFF1gE5GqauHNQK1Ih","date":"Jul 24, 2025","link":"https://finance.yahoo.com/news/stocks-making-big-moves-yesterday-130037748.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"financial results","round":null,"company":"Boston Scientific","layoffs":null,"summary":"Boston Scientific, a medical device company, experienced a 4.2% increase in its stock price on Wednesday following the release of its second-quarter financial results, which exceeded Wall Street expectations. The company also raised its full-year guidance, contributing to the positive market reaction. This growth-positive news highlights Boston Scientifics strong financial performance and optimistic outlook for the remainder of the year. The article also mentions other companies, such as Booz Allen Hamilton, which secured a $315 million contract with the U.S. Air Force, and SentinelOne, which saw a stock upgrade by Guggenheim.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["financial results","stock performance","guidance","analyst upgrade","contract award"],"date_of_event":"Wednesday","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"P8QFOYSObaoZ7WnhJnT9GKAYRojfwVXbL6iQ4ojvYgnvef64opVAiO","news_summary":"Stocks making big moves yesterday: Power Integrations, Booz Allen Hamilton, Wendy's, SentinelOne, and Boston Scientific","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"Xvmizq61QMF0nPhhUfonVAbVCmuwAP5Ep9gcIXTl6077okUSVI6UZO","date":"Jul 22, 2025","link":"https://finance.yahoo.com/news/microbot-medical-expands-commercial-leadership-123000496.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"management changes","round":null,"company":"Microbot Medical Inc.","layoffs":null,"summary":"Microbot Medical Inc. has appointed Christina Bailey as the new Vice President of Sales to strengthen its commercial leadership. Bailey, a former U.S. Olympian with extensive experience in medical device sales, is expected to lead the sales team for the anticipated launch of the LIBERTY Endovascular Robotic System. The LIBERTY system is currently an investigational device pending FDA 510(k) clearance and is not yet available for sale in the U.S. Microbot Medical aims to redefine endovascular robotics with its single-use, fully disposable robotic system. The company is focused on transitioning to a commercially focused entity and is preparing for the potential market introduction of its innovative product.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["leadership","sales","innovation","FDA approval","robotics"],"date_of_event":"July 22, 2025","product_stage":"pre-commercial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Management Changes"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":null,"structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"tHXQfQBhdbBmZ8l8e4CZKyVuUBD1EdvBfNKkpWLHRHmhVFdiNpQEfp","news_summary":"Microbot Medical® Expands Commercial Leadership with Appointment of Christina Bailey as VP of Sales","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"5Ksie58092eOlf3mjsgnx251707p8Wf67sDqZKKKFAlBaL8VBRCq5j","date":"Jun 24, 2025","link":"https://finance.yahoo.com/news/strength-seen-brainsway-bway-5-125400486.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"clinical trial","round":null,"company":"Brainsway Ltd.","layoffs":null,"summary":"Brainsway Ltd. experienced a 5.3% increase in its stock price, closing at $11.49, driven by positive market sentiment following successful clinical trial results for its Deep TMS therapy in treating Major Depressive Disorder (MDD). The study showed significant improvements in depression symptoms, enhancing investor confidence in the technologys market potential. The company is expected to report quarterly earnings of $0.04 per share, with revenues projected to rise by 23.8% from the previous year. The consensus EPS estimate has been revised 10% higher over the last 30 days, indicating potential for further stock price appreciation.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["clinical trial","depression","earnings","revenue","stock price"],"date_of_event":null,"product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"YM13nWQ1q0naG1L3pPJWdPTqOzQTdVdHFvDv9wlkDSOvwevN1sFF4F","news_summary":"Strength Seen in Brainsway (BWAY): Can Its 5.3% Jump Turn into More Strength?","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"u1bLYtdaxiElgJQU5rTlsjSNS3lSAqQXsJKXTpZUCZxzou8EIzPlfb","date":"Jun 17, 2025","link":"https://finance.yahoo.com/news/cisco-upgraded-coreweave-downgraded-wall-133532656.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"downgrade","round":null,"company":"Sarepta","layoffs":null,"summary":"Sarepta has been downgraded by H.C. Wainwright to Sell from Neutral, with a price target of $10, following the announcement of another death due to acute liver failure in a second non-ambulatory Duchenne muscular dystrophy patient treated with Elevidys. The company is suspending shipments of the drug to non-ambulatory DMD patients until an immunosuppressive regimen can be agreed upon with regulators and implemented. Piper Sandler also downgraded Sarepta to Neutral from Overweight, with a price target of $36, down from $70. These downgrades reflect concerns over the safety of Elevidys and the regulatory challenges facing Sarepta.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["downgrade","liver failure","drug suspension","regulatory issues","immunosuppressive regimen"],"date_of_event":null,"product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-negative","investment_amount":null,"structured_issues":["Product Stage","Customers"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage  #Customers","entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"gXHaIIX4J5KOjg4wkB0T1eFxKSd8hPGa4iYd7Bbp3BGPKAv6yBIKov","news_summary":"Cisco upgraded, CoreWeave downgraded: Wall Street’s top analyst calls","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"iWxutbsol98CF3Bi8piw4dsbTSkfz49F5BJRVvOeYWBUSEzOHWGFqK","date":"Mar 4, 2025","link":"https://en.globes.co.il/en/article-boston-scientific-buys-israeli-medical-device-co-sonivie-1001503621","source":"en.globes.co.il","visible":1,"analysis":{"tags":"acquisition","round":null,"company":"Boston Scientific","layoffs":null,"summary":"Boston Scientific has announced its acquisition of Israeli medical device company SoniVie for $360 million, with additional milestone payments up to $180 million. SoniVie, which has developed an intravascular ultrasound device for treating high blood pressure, is currently in a pivotal trial stage and may soon seek FDA approval. The acquisition is a strategic move for Boston Scientific, enhancing its portfolio with SoniVies innovative technology that offers a more effective treatment method compared to existing devices. The deal benefits several investors, including the heirs of Shmuel Almagor and various European venture capital funds. SoniVies technology was initially developed at Cardiosonic and later acquired by Accelmed Fund, which founded SoniVie.","partners":null,"customers":null,"eventType":null,"investors":["Supernova Invest","Andera Partners","TechWald","Omega Funds"],"confidence":10,"key_topics":["acquisition","ultrasound","hypertension","clinical trial","FDA approval"],"date_of_event":"March 4, 2025","product_stage":"pivotal trial","investment_date":null,"acquired_company":"SoniVie","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Acquisition"],"acquisition_amount":"$360 million","FDA approved/pending approval":"pending approval","AI technology developing/using":"using","structuredIssuesShow":"#Acquisition","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"crtKITAmwfIslVcxLlUO2wk2jKiVXTJk85tDXfpbHDrxhYipyGlAxx","news_summary":"The US medical device company will pay up to $540 million for the Rehovot-based intravascular ultrasound device developer for treating high blood pressure.","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"sxNbYFnjPtiZJvQbI2xCXsKheDARPJLe4P6eKKt4ddwt5LS9gaNS2o","date":"Mar 3, 2025","link":"https://www.calcalistech.com/ctechnews/article/sjp0kqmo1g","source":"www.calcalistech.com","visible":1,"analysis":{"tags":"acquisition","round":null,"company":"Boston Scientific","layoffs":null,"summary":"Boston Scientific is acquiring Israeli medical device company SoniVie for up to $540 million, focusing on ultrasound-based treatments for hypertension. The acquisition highlights the growing interest in renal denervation therapies, which offer an alternative to medication for high blood pressure. Boston Scientific will pay $360 million in cash for the remaining 90% of SoniVie, with an additional $180 million contingent on regulatory milestones. SoniVies TIVUS system, designed to treat hypertension by disrupting nerve signals in the renal arteries, has received FDA breakthrough device designation. The acquisition is expected to close in the first half of 2025, subject to regulatory approvals, and represents a strategic expansion into the renal denervation space.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["acquisition","hypertension","ultrasound","renal denervation","FDA"],"date_of_event":"first half of 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":"SoniVie","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Acquisition"],"acquisition_amount":"$540 million","FDA approved/pending approval":"pending approval","AI technology developing/using":"using","structuredIssuesShow":"#Acquisition","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"cMLJuI26IcdoZ22QtYLjVJDzi993EU1c2zBU3WPUHjYtF9u88cLBWe","news_summary":"The acquisition adds a promising alternative to traditional blood pressure medications.","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"vM2dXBXVg0a3LGtkVSRhJQJqiK7eT01VmjAHvYmS5LvXcLf4usCaVJ","date":"Mar 3, 2021","link":"https://en.globes.co.il/en/article-boston-scientific-to-buy-lumenis-surgical-division-for-1b-1001362827","source":"en.globes.co.il","visible":1,"analysis":{"tags":"Acquisition, Expansion","company":"Boston Scientific","layoffs":"Not mentioned","summary":"Boston Scientific has announced plans to acquire the global surgical business of Israeli medical laser company Lumenis for $1.07 billion in cash. The deal, which is expected to close in the second half of 2021, will see Boston Scientific expand the Yokneam offices into a world centre for laser surgery. Baring Private Equity Asia (BPEA), which will retain ownership of Lumenis global aesthetics and ophthalmology businesses, paid the same amount for Lumenis surgical business as it did for the entire company in 2019. Lumenis has 1,500 employees, including 450 in Israel.","partners":"Lumenis","customers":"Not mentioned","investors":"Baring Private Equity Asia","confidence":"10","key_topics":["Acquisition","Expansion","Laser Surgery","Urology","Investment"],"date_of_event":"March 3, 2021","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$1.07 billion","structured_issues":["Acquisition","Expand"],"acquisition_amount":"$1.07 billion","structuredIssuesShow":"#Acquisition  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"5bfcIuSsy7jH7qWhFqlmcD7ERbgkR7Y2m3FE9nUtsAQeFnT4Z7O6HC","news_summary":"Boston Scientific to buy Lumenis surgical division for $1.1b","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"PzHGCeTuz1jcGFIemtDRcmFOwJ6NruehwXHsX2klWCNm5cj61kTO5Y","date":"Oct 23, 2018","link":"https://www.calcalistech.com/ctech/articles/0,7340,L-3748221,00.html","source":"www.calcalistech.com","visible":1,"analysis":{"tags":"partnership","company":"Allium Medical Solutions Ltd.","layoffs":"","summary":"Allium Medical Solutions Ltd., an Israel-based minimally invasive products maker, has signed an agreement with Boston Scientific Corporation, granting the latter exclusive distribution rights in the U.S. for Alliums stenting assistance system. The agreement, announced in September, includes an option for Boston Scientific to acquire all of Gardia Medicals assets and rights within the first 27 months. Gardia Medical, a subsidiary of Allium, develops devices that enhance flexibility in stenting procedures and has received both European and U.S. FDA approvals. The deal is expected to generate NIS 70 million ($19 million) if expanded globally, with an upfront payment of NIS 25 million ($6.8 million). Despite the positive outlook, Alliums stock fell nearly 14% on the Tel Aviv exchange since the announcement.","partners":"Boston Scientific Corporation","customers":"","investors":"","confidence":9,"key_topics":["partnership","distribution","medical devices","stenting","FDA approval"],"date_of_event":"September 2018","valuation_amount":"","impact_on_company":"growth-positive","investment_amount":"","structured_issues":["Partners"],"acquisition_amount":"","structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"JOd4dHXWJNmVY9jvlBr5b9qg0Zr0bofoXLMWgR3RUtW2BDHllXsCei","news_summary":"Boston Scientific Signed a Distribution Deal with Israeli Allium Medical","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"Gr8yL0s8NYnEDu1QE1Qf1dQraTa4arxeBHXboayXgNL35yWEvQrQTA","date":"Oct 10, 2012","link":"https://en.globes.co.il/en/article-1000788924","source":"en.globes.co.il","visible":1,"analysis":{"tags":"acquisition","company":"Rhythmia Medical Inc.","layoffs":null,"summary":"Boston Scientific Corporation has acquired Rhythmia Medical Inc., a developer of cardiac arrhythmia treatment solutions, for $90 million, with potential additional milestone payments of up to $175 million. Rhythmia was founded by two expatriate Israelis, Leon Amariglio and Doron Harlev, and is based in Burlington, Massachusetts. The acquisition is expected to benefit Rhythmias Israeli investors, including former Ceragon CEO Shraga Katz and real estate tycoon Shir Roichman. The company had previously raised $20-30 million in its first financing round, primarily from private Israeli investors. The acquisition reflects a significant return on investment for these investors, with the potential for further gains if milestone payments are achieved.","partners":null,"customers":null,"investors":["Shraga Katz","Aviad Friedman","Elhanan Noam","Shir Roichman"],"confidence":9,"key_topics":["acquisition","investment","medical devices","cardiac arrhythmia","milestone payments"],"date_of_event":"October 10, 2012","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Acquired-by"],"acquisition_amount":"$90 million","structuredIssuesShow":"#Acquired-by","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"AIsIQsnwziDLPdL06oMC8BawPkqNnGS85L30htl9kniQRo1XbStHMO","news_summary":"Israeli investors profit from Boston Scientific's Rythmia acquisition - Globes\n","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"extensions":null,"events":null,"hide_reasons":[{"id":"75T5aG1f0dpqYFonup40lXNjO046zUH82TaHW1TAiIMf9aYAsSOl0d","reason":"No relevant activity"},{"id":"7KVi9S7qqUtO0WCsFclwqBEZluejfNYqWC1Uhx0tPHtDxtvxPPaCPH","reason":"No longer active"},{"id":"hoyKAmu4YJEHmhtLwCdeFldSnDwaVbPXOnH0RA9hKHCzAcHO6OOrXd","reason":"Pending approval"},{"id":"TC54H7CXyKO8GmPECkbyKJf8n34r70JlfJTJHfo85exRpLaKI1Efs9","reason":"Pending approval - External entity"}],"timeline":[{"id":"n3lUoA0sSkUpthBYshKGeeFGyLXzw8PBoV4BG5naVgIaTcslJWb09w","hub":null,"date":"1992-05-01","batch":"","token":"","amount":null,"hub_id":null,"source":"","ticker":"BSX","enddate":"","mnatype":null,"eventtype":"POEvent","granttype":null,"valuation":null,"investment":[],"hub_logokey":null,"hub_urlname":null,"wasacquired":null,"delistreason":null,"capitalraised":null,"stockexchange":"NYSE","eventvisibility":"Public","amountvisibility":null,"duetoacquisition":null,"isextensionround":null,"token_visibility":"","fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODIgdygCww","acquiredcompany_mna":null,"communitycompany_id":null,"isjointventuregrant":null,"acquiredcompany_spac":"Undisclosed","communitycompany_name":null,"communitycompany_type":null,"stockexchange_logokey":"$gCUzHIIl5WdaUySSBVfr4ukCJPjuwKJMFXjiY09JCLUNERZRom14T0","acquiredcompany_mna_id":null,"fundingtypefundingtype":null,"acquiredcompany_reverse":null,"acquiredcompany_spac_id":null,"communitycompany_hidden":null,"communitycompany_fullurl":null,"communitycompany_logokey":null,"communitycompany_urlname":null,"acquiredcompany_reverse_id":null,"acquiredcompany_mna_logokey":null,"acquiredcompany_mna_urlname":null,"acquiredcompany_mna_homepage":null,"acquiredcompany_spac_logokey":null,"acquiredcompany_spac_homepage":null,"acquiredcompany_reverse_logokey":null,"acquiredcompany_reverse_urlname":null,"acquiredcompany_reverse_homepage":null,"hub_logourl":"/assets/empty-state.svg","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$gCUzHIIl5WdaUySSBVfr4ukCJPjuwKJMFXjiY09JCLUNERZRom14T0","communitycompany_logourl":"/assets/empty-state.svg","acquiredcompany_mna_logourl":"/assets/empty-state.svg","acquiredcompany_spac_logourl":"/assets/empty-state.svg","acquiredcompany_reverse_logourl":"/assets/empty-state.svg","style":"","hiddenCompanyTooltip":""}],"techcommunityinvolvement":null,"tags":["medical-devices","manufacturing"],"investments":[],"funds":[],"databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"50,000+","fundingtype":"Multinational","parsedName":"Boston Scientific","logourl":"https://storage.googleapis.com/clean-finder-353810/$RH4cKLPIzbWARH9LQZDsvuKZetnjFnXpTSc06OqvMLyLx28ZDnpzFt.jpg","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$RH4cKLPIzbWARH9LQZDsvuKZetnjFnXpTSc06OqvMLyLx28ZDnpzFt.jpg","teamMembersNumber":3,"nationality":"Foreign","communityinvolvement":[],"popup_claim_profile":"false","claimedBadge":"none","display":{"mainContact":"none"},"mainContact":{},"_eventview":{"publicoffering_exit":[],"privateequityfunding":[],"nonequityfunding":[],"merger_acquisitions":[],"others":[]}}